CheckMate-227 Study of Frontline Nivolumab and Ipilimumab in Advanced NSCLC

Dr Vamsidhar Velcheti explains the 4-year data updates to the CheckMate 227 trial, which investigated PD-L1 monotherapy plus chemotherapy for advanced NSCLC.

Related Videos
View All
Related Content